Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of January 2026 for Enlivex Therapeutics Ltd., a company organized under the laws of Israel. The filing was submitted on January 26, 2026, to disclose a material corporate event regarding the company's treasury assets.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event disclosure and does not contain financial statements or performance metrics.
Material Changes
Effective January 21, 2026, Enlivex Therapeutics Ltd. announced that its treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange. This listing represents a material change in the liquidity and accessibility of the company's digital asset holdings.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future operations, or a detailed discussion of risks and contingencies beyond the announcement of the token listing. No unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the trading status and liquidity of the RAIN token on the WhiteBIT exchange.
- Confirm the total quantity of RAIN tokens held by Enlivex Therapeutics Ltd. as part of its treasury.
- Review the full text of the press release (Exhibit 99.1) for additional details on the listing terms.
- Assess the potential impact of cryptocurrency market volatility on the company's balance sheet.